NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) reported accelerating commercial momentum with record procedure volume for its OneRF® brain ablation system and early clinical success in treating trigeminal neuralgia, while advancing its platform technology into three new market opportunities each exceeding $1 billion annually in the United States. The company's strategic focus on brain, pain, and advanced drug delivery markets positions it for significant growth as it approaches key milestones in 2026.
The importance of NeuroOne's progress lies in its potential to transform treatment for debilitating neurological conditions while creating substantial shareholder value. The company's brain ablation program, commercialized through an exclusive distribution partnership with Zimmer Biomet, delivered its strongest quarter in Q1 fiscal 2026 since its 2024 launch, with nearly 50% of all ablations performed since introduction completed in that single quarter alone. This growing adoption validates the technology's clinical utility while providing margin benefits since Zimmer Biomet covers all marketing and sales costs under the distribution agreement.
Clinical outcomes reinforce the platform's potential. Following treatment with the OneRF® ablation system, a professional pianist from Chicago resumed his career and a teenage girl who experienced an average of 10 seizures nightly became seizure-free for over a year. The first nine patients treated for trigeminal neuralgia—one of medicine's most severe pain conditions affecting approximately 150,000 new patients annually in the U.S.—are all reportedly pain-free following FDA 510(k) clearance last August. These outcomes demonstrate meaningful improvements over existing standards of care.
The company's expansion into larger markets represents its most significant growth opportunity. Beyond currently approved applications representing over $200 million in U.S. market opportunity, NeuroOne is advancing programs in drug delivery, basivertebral nerve ablation (BVNA), and spinal cord stimulation—each representing addressable markets that could exceed $1 billion annually. The strategic interest in these areas is validated by transactions like Boston Scientific's approximately $850 million acquisition of Relievant Medsystems, developer of the Intracept® basivertebral nerve ablation system, representing roughly a 12× multiple of expected revenue at the time. The category has also attracted new product launches from companies such as Stryker, further validating clinical need and expanding long-term market opportunity.
NeuroOne's platform advantage lies in leveraging existing FDA-cleared technology to efficiently develop differentiated products for these large markets. The drug delivery system is now six months ahead of its original development schedule, targeting commercial readiness for investigational clinical or animal studies by Q3 fiscal 2026, initially focused on glioblastoma and gene therapies. The BVNA program leverages existing OneRF® components while utilizing multi-contact sEEG probes that offer doctors more flexibility during placement. The spinal cord stimulation percutaneous paddle lead has initiated a six-month animal study in preparation for first-in-man studies, with the system generating physician interest at recent medical meetings.
Financially, the company maintains a strong position with zero debt, $3.6 million in cash and cash equivalents, $2.7 million in accounts receivable, and $6.8 million in working capital as of December 31, 2025. NeuroOne guides to at least $10.5 million in product revenue for fiscal year 2026, a minimum 17% increase over fiscal year 2025, excluding potential contributions from the trigeminal nerve ablation clearance. The company is also in active discussions that could generate non-dilutive cash in 2026.
To maintain Nasdaq listing compliance, the company is requesting shareholder approval for a reverse stock split at its April 3, 2026 Annual Meeting, emphasizing this as a structural compliance mechanism that leaves total market capitalization and shareholder proportional ownership unchanged. The company's growing intellectual property portfolio includes 13 U.S. patents issued or pending plus four internationally, supporting its platform technology across multiple applications. With four FDA clearances secured to date and a commercial infrastructure through Zimmer Biomet providing national reach without corresponding SG&A burden, NeuroOne is positioned for several strategic and commercial inflection points beginning in 2026 across its expanding pipeline.
